# Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

> **NCT06657391** · PHASE2 · RECRUITING · sponsor: **Rongrong Liu** · enrollment: 396 (estimated)

## Conditions studied

- Transfusion Dependent Thalassemia

## Interventions

- **DRUG:** recombinant humanized anti-CD25 monoclonal antibody

## Key facts

- **NCT ID:** NCT06657391
- **Lead sponsor:** Rongrong Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06657391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06657391, "Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06657391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*